March 04, 2022 at 05:14PM Privigen

Product approval information is indicated for the treatment of:
•Primary humoral immunodeficiency;
•Chronic immune thrombocytopenic purpura (ITP) in patients age 15 years and older;
•Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/yxvaJQj